Sandoz Targeted Over Generic Cancer Drug Fusilev

Law360, New York (January 23, 2012, 6:32 PM EST) -- Pharmaceutical company Sandoz Inc. was hit Friday with a patent infringement suit in Nevada federal court by oncology drug specialist Spectrum Pharmaceuticals Inc. and the University of Strathclyde, a Scottish institution, over plans to make a generic version of cancer drug Fusilev.

The suit was prompted by Sandoz’s abbreviated new drug application filed with the U.S. Food and Drug Administration to manufacture 175- and 250-milligram dosage strength versions of levoleucovorin, the generic version of Fusilev.

According to the complaint, Sandoz notified the plaintiffs in December about...
To view the full article, register now.